GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Algorae Pharmaceuticals 1AI.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.01

—

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Algorae Pharmaceuticals — daily ASX:1AI

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Algorae Pharmaceuticals on TradingView ↗
Market value
A$15.2m
Last close × shares
Volume
3.5m
Shares, 9 Nov 2026

About Algorae Pharmaceuticals

Its shares trade on ASX under the ticker 1AI.AX. It has been listed since 1 September 2004. In the fiscal year to 30 June 2025, it reported revenue of A$141,100 and a net loss of A$803,000. At that date it held total assets of A$2.4m and shareholders' equity of A$2.2m.

Algorae Pharmaceuticals Ltd is a AU-based company operating in Biotechnology industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The firm is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.

Figures and description from our data supplier, not checked against the company's own report.

More about Algorae Pharmaceuticals →

Latest on Algorae Pharmaceuticals

Our reporting

We have not reported on Algorae Pharmaceuticals yet.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Algorae Pharmaceuticals's ticker?

Algorae Pharmaceuticals trades as 1AI.AX on ASX, under ISIN AU0000296022.

What was Algorae Pharmaceuticals's last closing price?

0.01 on 9 Nov 2026. The figure is in AUD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.